Approval · Notice of Compliance 5664 · 1994
REACTINE: Notice of Compliance 5664
Issued September 21, 1994
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5664
- Date
- September 21, 1994
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Provides for nonprescription sale
- Therapeutic class
- Histamine h1 receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE | 01900951 | — |
| REACTINE | 01900986 | Cancelled Post Market |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 5 MG per TAB
- CETIRIZINE HYDROCHLORIDE 10 MG per TAB